CORRECTION article

Front. Pharmacol., 30 September 2024

Sec. Neuropharmacology

Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1491886

Corrigendum: Long-term efficacy and reduced side-effects of buprenorphine in patients with moderate and severe chronic pain

  • 1. Department of Pain Management—AO “Ospedale dei Colli”–Monaldi Hospital, Napoli, Italy

  • 2. Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy

  • 3. Department of Experimental Medicine, Division of Pharmacology, University of Campania “Luigi Vanvitelli”, Naples, Italy

In the published article, there was an error in Figures 1, 4, 5 as published. The figures were mismatched with their respective images.

Figure 1 should display the image originally intended for Figure 5; the caption remains correct. The corrected Figure 1 and its caption appear below.

FIGURE 1

Figure 4 should display the image originally intended for Figure 1; the caption remains correct. The corrected Figure 4 and its caption appear below.

FIGURE 4

Figure 5 should display the image originally intended for Figure 4; the caption remains correct. The corrected Figure 5 and its caption appear below.

FIGURE 5

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

chronic pain, opioids, tolerance, ransdermal patches, pain relief, opioid crisis

Citation

Papa A, Salzano AM, Di Dato MT, Desiderio V, Buonavolontà P, Mango P, Saracco E, Tammaro D, Luongo L and Maione S (2024) Corrigendum: Long-term efficacy and reduced side-effects of buprenorphine in patients with moderate and severe chronic pain. Front. Pharmacol. 15:1491886. doi: 10.3389/fphar.2024.1491886

Received

05 September 2024

Accepted

10 September 2024

Published

30 September 2024

Volume

15 - 2024

Edited and reviewed by

Álvaro Llorente-Berzal, Autonomous University of Madrid, Spain

Updates

Copyright

*Correspondence: Alfonso Papa,

†These authors have contributed equally to this work and share last authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics